BSX vs ABT Comparison: AI Score, Valuation, Performance and Upside
Compare Boston Scientific's cardiovascular device pipeline against Abbott's diversified devices, diagnostics, and nutrition business.
Use this Boston Scientific vs Abbott Laboratories comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
BSX holds the edge across 3 of 5 key metrics in this comparison. ABT has delivered stronger 1-year price return (-23.75% vs -55.88%), though BSX has the better forward P/E setup (13.64x vs 16.81x for ABT). On fundamentals, ABT is growing revenue faster (13.00%), while BSX maintains the higher operating margin (22.90%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for BSX (+33.84%) than for ABT (+17.96%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | BSX | ABT |
|---|---|---|
| AI scorei | 39.8 | 50.3 |
| AI ranki | #1203 | #528 |
| Latest closei | $43.34 | $102.61 |
| 1M returni | -16.67% | -10.33% |
| 6M returni | -37.99% | -4.27% |
| 1Y returni | -55.88% | -23.75% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BSX | ABT |
|---|---|---|
| 1Y ago | $4.41K (-55.9%) started 2025-09-18 | $7.63K (-23.7%) started 2025-09-18 |
| 5Y ago | $9.93K (-0.7%) started 2021-09-20 | $9.47K (-5.3%) started 2021-09-20 |
| 10Y ago | $18.43K (+84.3%) started 2016-09-19 | $34.41K (+244.1%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BSX | ABT |
|---|---|---|
| Market capi | $67.88B | $176.41B |
| Trailing P/Ei | 18.96 | 32.99 |
| Forward P/Ei | 13.64 | 16.81 |
| Price/Salesi | N/A | 5.49 |
| EV/Revenuei | 3.82 | 4.38 |
| Analyst targeti | $62.69 | $120.26 |
| Target upsidei | +33.84% | +17.96% |
| Metric | BSX | ABT |
|---|---|---|
| Revenue growthi | 7.50% | 13.00% |
| Earnings growthi | 15.10% | -47.50% |
| EPS growthi | +15.10% | -47.50% |
| FCF margini | +11.68% | +15.48% |
| Operating margini | 22.90% | 14.71% |
| Profit margini | 17.50% | 11.65% |
| ROIC proxyi | 15.34% | 10.58% |
| Return on equityi | 15.34% | 10.58% |
| Dividend yieldi | N/A | 2.47% |
| Payout ratioi | 0.00% | 78.96% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.57 | 0.59 |
| Debt/equityi | 50.15 | 63.21 |
| Current ratioi | 1.24 | 1.38 |
| Quick ratioi | 0.56 | 0.80 |
Over the past year, BSX and ABT have moved weakly in the same direction (correlation of 0.37), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BSX | ABT |
|---|---|---|---|
| 1Y | Growthi | -55.88% | -23.75% |
| CAGRi | -55.90% | -23.76% | |
| Volatilityi | 38.19% | 26.76% | |
| Sharpe ratioi | -2.07 | -1.05 | |
| Sortino ratioi | -2.42 | -1.45 | |
| Max drawdowni | 59.39% | 39.57% | |
| Current drawdowni | 58.72% | 24.89% | |
| Avg drawdowni | 31.27% | 19.30% | |
| Ulcer Indexi | 38.01% | 22.21% | |
| Max daily dropi | 17.59% | 10.04% | |
| Max wkly dropi | 19.50% | 13.11% | |
| 5Y | Growthi | -0.69% | -11.88% |
| CAGRi | -0.14% | -2.50% | |
| Volatilityi | 26.62% | 23.04% | |
| Sharpe ratioi | -0.04 | -0.19 | |
| Sortino ratioi | -0.05 | -0.27 | |
| Max drawdowni | 60.58% | 40.85% | |
| Current drawdowni | 59.92% | 26.48% | |
| Avg drawdowni | 10.41% | 17.55% | |
| Ulcer Indexi | 18.72% | 19.81% | |
| Max daily dropi | 17.59% | 10.04% | |
| Max wkly dropi | 19.50% | 13.11% | |
| 10Y | Growthi | +84.35% | +189.17% |
| CAGRi | +6.31% | +11.21% | |
| Volatilityi | 27.74% | 24.01% | |
| Sharpe ratioi | 0.20 | 0.38 | |
| Sortino ratioi | 0.27 | 0.54 | |
| Max drawdowni | 60.58% | 40.85% | |
| Current drawdowni | 59.92% | 26.48% | |
| Avg drawdowni | 9.30% | 10.84% | |
| Ulcer Indexi | 15.42% | 14.55% | |
| Max daily dropi | 17.59% | 10.04% | |
| Max wkly dropi | 19.55% | 16.72% |
| Category | BSX | ABT |
|---|---|---|
| Company | BSX | ABT |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.